Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TSHA with free AI briefings, catalyst countdowns, and dilution alerts.

TSHA · Taysha Gene Therapies, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$422.8M Cash on Hand
34.6mo Cash Runway
Follow TSHA by email Get an email when TSHA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TSHA, unsubscribe in one click. Privacy

📣 What TSHA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
TSHA-101 Infantile GM2 Gangliosidosis (Disorder) Phase 1/2 · NCT04798235 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TSHA holds $422.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $36.7M/quarter from operations, an estimated runway of 34.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 22 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TSHA files for a raise →

👥 Who Owns TSHA

Insiders 4.1% Institutions (282 holders) 94.9% Public and other holders 1%
HolderTypeShares% of sharesAs of
RA Capital Management, L.P. Institution (13G, 5%+) 32,886,242 10.09% 2026-06-30
RTW Investments, LP Institution (13G, 5%+) 20,689,084 6.35% 2026-03-31
Vestal Point Capital, LP Institution (13G, 5%+) 18,000,000 5.52% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 17,852,291 5.48% 2025-12-31
Morgan Stanley Institution (13G, 5%+) 16,244,339 4.98% 2026-06-30
Sean P. Nolan
Chief Executive Officer, Director · +3.19M options
Insider 4,443,802 1.36% 2026-01-23
Paul B Manning
10% owner
Insider 4,000,000 1.23% 2025-05-30
John A III Stalfort
Director · +254,357 options
Insider 2,060,849 0.63% 2026-06-01
Kamran Alam
CHIEF FINANCIAL OFFICER · +1.45M options
Insider 1,442,131 0.44% 2026-02-04
Sukumar Nagendran
President and Head of R&D, Director · +1.17M options
Insider 936,410 0.29% 2026-07-10
Phillip B. Donenberg
Director · +254,357 options
Insider 241,289 0.07% 2026-06-01
Alison S Long
Director · +254,357 options
Insider 127,178 0.04% 2026-06-01

Share count 326,045,530 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TSHA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TSHA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.